Her’s exact test (sex, organomegaly). JNK1 medchemexpress p-value from Pearson’s chi-square
Her’s exact test (sex, organomegaly). P-value from Pearson’s chi-square test for Hasford risk category and overall performance status. Unknowns have been excluded from significance tests. Pts=patients.NIH-PA Author ManuscriptPageNIH-PA Author ManuscriptNIH-PA Author ManuscriptBr J Haematol. Author manuscript; readily available in PMC 2015 January 01.TableTreatment outcomes of 145 CML-CP individuals by therapy arm.IM400 (N=72) Pts 59 63 4 5 N=49 33 N=45 N=53 67 520 35 85 714 0.040 N=41 7 four five 6 24 3 4 12 0.49 88 784 66 90 816 0.38 82 710 62 85 752 0.40 95 CI Pts 95 CI P IM800 (N = 73)Total haematologic response (confirmed)Complete haematologic response (any)Resistant diseaseNot evaluableComplete cytogenetic responseMolecular response at 1 year : 16 4 four 9 21 ten 19 92 0.13 9 21 14 26 150 0.023 36 221 28 53 397 0.3-log decrease (MMR)4-log reduce(MR4.0)four.5-log lower(MR4.5)One-sided p-value from Fisher’s exact test for superior outcome in the IM800 arm.Br J Haematol. Author manuscript; available in PMC 2015 January 01.Depending on blood specimens collected 29506 days just after randomization (if a patient’s molecular response was tested additional than as soon as during that interval, only the result obtained closest to day 365 was integrated in this analysis).NIH-PA Author ManuscriptDeininger et al. PageNIH-PA Author ManuscriptNIH-PA Author 5-HT5 Receptor manufacturer ManuscriptTableTreatment outcomes of 111 individuals with CML-CP based on molecular response at 3 monthsIM400 10 (N=19) Pts 18 0 N=15 six N=10 1 0 0 0 01 three 11 29 0.38 0 0 04 10 29 156 0 01 3 11 29 0.38 0 0 04 14 40 248 ten 05 11 41 221 0.080 0 0 04 26 74 576 0.0001 0.020 0.074 N=27 N=9 N=35 40 168 23 85 666 0.0038 3 50 128 25 93 769 0.031 N=27 N=6 N=28 three 1 1 95 7400 33 92 768 0.83 9 82 488 44 98 8800 0.095 95 CI Pts 95 CI P Pts 95 CI Pts 95 CI P 10 (N=36) ten (N=11) 10 (N=45) IMCHRNot evaluableCCyRMR at 1 year3-log (MMR)4-log(MR4.0)four.5-log(MR4.5)One-sided p-value for poorer outcome in patients with 10 reduction in transcript at three months, based on Fisher’s precise test.Consists of 84 CHRs (40 IM400, 44 IM800) accomplished on or just before collection of 3-month specimen.All CCyRs had been accomplished after day 90 specimen collection, except 1 IM400 patient four with ten Reduction.Br J Haematol. Author manuscript; readily available in PMC 2015 January 01.Based on blood specimens collected 29506 days after randomization (if a patient’s molecular response was tested additional than when throughout that interval, only the result obtained closest to day 365 was incorporated within this evaluation).NIH-PA Author ManuscriptDeininger et al. PageNIH-PA Author ManuscriptNIH-PA Author ManuscriptTableToxicities of 144 CML-CP individuals who received assigned therapy, by treatment armIM400 (N=72) All grades Haematologic toxicities 47 (65 ) 23 (32 ) 1 ( 1 ) 24 (33 ) Fluid retention 42 (58 ) 0 ( 0 ) Gastrointestinal toxicities 28 (39 ) 36 (50 ) 11 (15 ) 11 (15 ) Other non-haematologic toxicities 47 (65 ) 33 (46 ) 19 (26 ) 9 (13 ) 3 ( 4 ) 0 ( 0 ) 7 (10 ) 0 ( 0 ) 0.14 1 ( 1 ) 9 (13 ) 1 ( 1 ) 0.49 1 ( 1 ) 36 (50 ) 4 ( 6 ) 0.0012 2 ( three ) 42 (58 ) 8 (11 ) 0.011 0 ( 0 ) 57 (79 ) 11 (15 ) 0.0006 0 ( 0 ) 16 (22 ) 0 ( 0 ) 0.16 1 ( 1 ) 20 (28 ) 0 ( 0 ) 0.036 2 ( 3 ) 42 (58 ) 2 ( 3 ) 0.043 1 ( 1 ) 40 (56 ) 6 ( eight ) 0.0088 0 ( 0 ) 2 ( three ) 0 ( 0 ) 0.25 three ( 4 ) 50 (69 ) 2 ( three ) 0.15 6 ( 8 ) 46 (64 ) 14 (19 ) 0.0001 1 ( 1 ) 1 ( 1 ) 1 ( 1 ) 0.75 eight (11 ) 33 (46 ) 12 (17 ) 0.043 five ( 7 ) 59 (82 ) 8 (11 ) 0.0067 Grade 3 All grades Grade 3 P I.